Eli Lilly turns to South Korean RNA editing biotech for hearing loss in deal worth $1.3B

Extensive research indicates that feeling lonely is not just a mental state, but a significant risk factor for heart disease, dementia, diabetes, and even hearing loss.

Eli Lilly strikes $1.3bn gene therapy deal with Rznomics - Pharmaceutical Technology

The deal gives Lilly access to the company’s RNA-editing platform to develop therapies for sensorineural hearing loss.

Eli Lilly turns to South Korean RNA editing biotech for hearing loss in deal worth $1.3B

Eli Lilly is building out its gene therapy pipeline for hearing loss through a new deal with RNA-focused startup Rznomics. The Indianapolis drug giant and Seongnam-based biotech will work together on sensorineural hearing loss in ...